Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial Meeting Abstract
| Authors: | Loriot, Y.; Pant, S.; Witt, O.; Reardon, D. A.; Doi, T.; Qin, S.; Tabernero, J.; Iyer, G.; Massard, C.; Arnold, D.; Lugowska, I.; Carranza, O.; Gutierrez, M.; Winter, H.; Sweiti, H.; Thomas, S.; Gormley, M.; Zhang, J.; Triantos, S.; Schuler, M. H. H. |
| Abstract Title: | Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S273 |
| Language: | English |
| ACCESSION: | WOS:001087480200224 |
| DOI: | 10.1016/j.annonc.2023.09.2953 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 230P -- Source: Wos |
